BRaf inhibitors, dabrafenib and SB590885, enhance ERK1/2 signalling in cardiomyocytes and increase angiotensin II-induced cardiac hypertrophy.
Event:
Heart Failure 2017 - 4th World Congress on Acute Heart Failure
Topic:
Cell Signalling
Session:
Basic Science - Therapeutic approach
